Tempus Announces Latest Immunotherapy Project

Tempus Announces Latest Immunotherapy Project

CHICAGO, Nov. 15, 2017 (GLOBE NEWSWIRE) — Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, along with Georgetown Lombardi Comprehensive Cancer Center, in Washington, D.C., and John Theurer Cancer Center at Hackensack Meridian HealthHackensack University Medical Center announce a new research … Continued

COMPUTING CARE

BY ERIN MCCALLISTER, SENIOR EDITOR Tempus Labs Inc. has created a machine learning tool that can help physicians make better treatment decisions by comparing a cancer patient’s genetic and clinical profile to those of thousands of other patients with known treatment outcomes. The tool supplements molecular profiling conducted in the company’s CLIA lab by placing … Continued

Enlisting technology in the war against cancer

Eric Lefkofsky, founder and CEO at Tempus participates in keynote conversation with Carleen Hawn, CEO of Healthspottr focused on enlisting technology in the war against cancer.

Tempus and Sanford Health Collaborate on Personalized Medicine Initiative

CHICAGO, Nov. 01, 2017 (GLOBE NEWSWIRE) — Tempus, a rapidly-growing technology company focused on collecting and integrating molecular and clinical data and Sanford Health, one of the largest health system in the nation will collaborate to identify targeted therapies and clinical trials for breast cancer patients. As part of the collaboration, Sanford Health will collect … Continued

Tempus Unveils Tempus xT, 595 Gene Panel Aimed at Empowering Data-Driven Cancer Care

CHICAGO, Oct. 19, 2017 (GLOBE NEWSWIRE) — Tempus today announced the launch of its new comprehensive genomic sequencing panel, Tempus xT, which analyzes 595 genes relevant to the diagnosis, prognosis and therapeutic targeting of cancer. The panel will sequence a patient’s tumor DNA and RNA, as well as a matched normal blood or saliva to … Continued

Tempus and the OHSU Knight Cancer Institute Collaborating on Personalized Medicine Data Initiative

CHICAGO, Sept. 28, 2017 (GLOBE NEWSWIRE) — Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and the Knight Cancer Institute at OHSU in Portland, Oregon, have announced a new collaboration aimed at improving outcomes for breast, pancreatic, and prostate cancer patients. … Continued

Tempus Announces $130M Raised

CHICAGO, Sept. 25, 2017 (GLOBE NEWSWIRE) — Tempus announced today that it closed a $70M, Series C, round of venture funding co-led by New Enterprise Associates (NEA) and Revolution Growth. This latest round brings the two-year-old company’s total funding to $130M. Tempus has spent the last two years building a series of data pipelines to … Continued

Tempus and Cleveland Clinic Collaborate on Personalized Medicine Initiative

CHICAGO, Sept. 14, 2017 (GLOBE NEWSWIRE) — Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and Cleveland Clinic Taussig Cancer Institute will collaborate on a precision medicine initiative aimed at improving outcomes for patients diagnosed with cancer. As part of the … Continued

Tempus and University of California Davis Comprehensive Cancer Center Announce Personalized Medicine Partnership for Cancer Patients

CHICAGO, Aug. 31, 2017 (GLOBE NEWSWIRE) — Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data and University of California Davis Comprehensive Cancer Center are collaborating on a precision medicine partnership to advance clinical care with Next Generation Sequencing analysis, focused initially … Continued

Tempus Selected as Sequencing and Analytics Provider by the Prostate Cancer Clinical Trials Consortium forPhase II Clinical Trial

Tempus Selected as Sequencing and Analytics Provider by the Prostate Cancer Clinical Trials Consortium for Phase II Clinical Trial Chicago, August 17 – Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data announced today that it was selected by the Prostate Cancer … Continued